Jan 26 (Reuters) - The U.S. Food and Drug Administration approved Rockwell Medical Inc's drug for treating iron loss in chronic kidney disease patients on dialysis, sending the company's shares up about 15 percent in premarket trading.
The drug, Triferic, replaces the 5-7 mg of iron patients tend to lose during each dialysis session.
01:28 Billionaire investor Wilbur Ross confirmed as Trump’s secretary of commerce12
17:35 Boeing to open first European factory, to invest 20 million pounds24
17:23 Philadelphia 76ers trade Nerlens Noel to Dallas Mavericks25
07:15 Telefonica to sell up to 40 percent of Telxius to KKR for 1.3 billion euros22